Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 1, 2018

BioPharm International

  • BioPharm International-04-01-2018
  • Volume 31
  • Issue 4

Automated Benchtop Pipette

The Concentrating Pipette Select from InnovaPrep is a small automated benchtop instrument that can concentrate contaminates from large volumes of liquids for improved detection.

The Concentrating Pipette Select from InnovaPrep is a small automated benchtop instrument that can concentrate contaminates from large volumes of liquids for improved detection. The instrument allows for contamination screening of liquid samples up to 5L and lets users choose from six versions of interchangeable, high-flow filtered pipette tips that feature different specifications to concentrate proteins, viruses, DNA, bacteria, whole cells, fungal spores, or other particles. Recovered particles are delivered in seconds and ready for analysis using user method of choice, according to the company.

Applications for the pipette include biological and particulate contamination monitoring in the environment, as well as monitoring the integrity of various ingredients including water, intermediate products such as cell culture media, and finished products including parenteral fluids and compounded drugs.

According to InnovaPrep, when used as a front-end to rapid molecular methods for quality assurance/quality control monitoring, the instrument allows for sample-to-answer within a single shift, improving detection of trace contamination. 

InnovaPrep


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.